Barclays’s BioVie BIVI Stock Holding History

Barclays’s Portfolio BIVI Stock Details BIVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$1K	–	5298
2024 Q2	$1K	Sell	25 -87	-78%	-$4.16K	﹤0.01%	4681
2024 Q1	$5.9K	Sell	112 -64	-36%	-$6.56K	﹤0.01%	4855
2023 Q4	$22.2K	Buy	176 +165	+1,500%	+$49.6K	﹤0.01%	4891
2023 Q3	$3.69K	Buy	11 +4	+57%	+$1.56K	﹤0.01%	4418
2023 Q2	$3K	Sell	7 -534	-99%	-$360K	﹤0.01%	4305
2023 Q1	$437K	Buy	541 +292	+117%	+$194K	﹤0.01%	3359
2022 Q4	$193K	Buy	+249	New	+$135K	﹤0.01%	3860

Other funds holding BIVI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ZIG

Zullo Investment Group Scranton, Pennsylvania $264M AUM 26.77% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

UCMOK

United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Barclays's BIVI Position: Q3 2024 in Review

Barclays sold out of BioVie (BIVI) in Q3 2024, closing a stake of 25 shares — an estimated $1K sold.

Barclays first reported a position in BIVI in Q4 2022 and held it in 7 quarters. The position peaked at $437K in Q1 2023. 25 funds tracked by Wall St. Rank hold BIVI as of Q3 2024.

Barclays reported no remaining BioVie position as of Q3 2024 after selling out during the quarter.
Barclays sold 25 BioVie shares in Q3 2024, an estimated $1K.
Barclays first reported a position in BioVie in Q4 2022 and held it in 7 quarters.
Barclays's BioVie position peaked at $437K in Q1 2023.
25 funds tracked by Wall St. Rank held BioVie as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.